Standard Operating Procedure for Cross-Contamination Control in Bioreactor Operations for Biosimilars
| Department | Biosimilars |
|---|---|
| SOP No. | SOP/BS/092/2025 |
| Supersedes | SOP/BS/092/2022 |
| Page No. | Page 1 of 11 |
| Issue Date | 04/05/2025 |
| Effective Date | 06/05/2025 |
| Review Date | 04/05/2026 |
1. Purpose
To define systematic measures for controlling cross-contamination in bioreactor operations during biosimilar manufacturing. The SOP ensures implementation of controls to avoid cross-mixing of products, microbial ingress, or carryover of residues between batches or processes.
2. Scope
This SOP is applicable to all operations involving equipment, raw materials, personnel, and utilities within bioreactor suites at biosimilar manufacturing facilities.
3. Responsibilities
- Manufacturing Staff: Follow hygiene, gowning, and material segregation procedures strictly.
- QA Personnel: Monitor environmental control records and verify cleaning validations.
- Engineering Team: Maintain integrity of HVAC systems and verify equipment CIP/SIP performance.
4. Accountability
The Head of Manufacturing is accountable for ensuring cross-contamination control is implemented, monitored, and continually improved through risk assessment and training.
5. Procedure
5.1 Facility and Zonal Segregation
- Ensure bioreactor operations are performed in dedicated cleanroom zones with restricted access.
- Follow unidirectional flow of personnel and materials.
- Label equipment and areas as per product campaign or batch ID.
5.2 Equipment Cleaning and Validation
- Use validated cleaning procedures (refer SOP/BS/098/2025) post each batch.
- Visually inspect all contact surfaces for residue.
- Conduct swab/Rinse Test with LOD ≤10 ppm for previous product or protein.
- Document in Annexure-1: Equipment Cleaning Log.
5.3 Product and Material Segregation
- Segregate raw materials by product and lot using dedicated containers and color-coded labels.
- Do not store different in-process materials together in common tanks.
- Transport intermediates in sealed, pre-sterilized containers.
5.4 Personnel Practices
- Ensure operators working on a specific product do not move to other zones without complete gown change and sanitization.
- Train personnel on risks of cross-contamination and proper gowning behavior.
5.5 Environmental Controls
- Maintain differential pressure between rooms (+10 to +15 Pa) to prevent cross-airflow.
- Verify HEPA filters monthly and HVAC status before batch start.
- Perform routine environmental monitoring (settle plate, swab) and trending.
5.6 Changeover Between Products
- Execute full cleaning, disinfection, and verification as per product changeover matrix.
- Approve changeover activities through QA and retain approval in Annexure-2.
6. Abbreviations
- HVAC: Heating Ventilation and Air Conditioning
- CIP: Clean-In-Place
- SIP: Sterilize-In-Place
- QA: Quality Assurance
7. Documents
- Equipment Cleaning Log – Annexure-1
- Product Changeover Approval Form – Annexure-2
8. References
- ICH Q9 – Quality Risk Management
- WHO TRS 1010 Annex 4 – Cross Contamination and Mix-ups Prevention
9. SOP Version
Version: 2.0
10. Approval Section
| Prepared By | Checked By | Approved By | |
|---|---|---|---|
| Signature | |||
| Date | |||
| Name | |||
| Designation | |||
| Department |
11. Annexures
Annexure-1: Equipment Cleaning Log
| Date | Equipment ID | Product | Cleaning Performed By | Swab Results | QA Reviewed |
|---|---|---|---|---|---|
| 04/05/2025 | BR-104 | Rituximab | Sunita Reddy | Pass | Yes |
Annexure-2: Product Changeover Approval Form
| Previous Product | Next Product | Cleaning Completed On | Verified By (QA) | Changeover Approved |
|---|---|---|---|---|
| Etanercept | Adalimumab | 03/05/2025 | Rajesh Kumar | Yes |
Revision History:
| Revision Date | Revision No. | Revision Details | Reason for Revision | Approved By |
|---|---|---|---|---|
| 04/05/2025 | 2.0 | Included changeover approval and HVAC differential pressure control | GMP upgrade |